For estrogen receptor positive breast cancer, Fulvestrant, a full estrogen receptor antagonist31, for prostate cancer, MDV-3100, a second-generation androgen receptor inhibitor32, and for lung cancer, GSK1059615, a dual PI3K/mTOR inhibitor6 were chosen as targeted treatments. This evidence concerns the gene ESR1 and prostate cancer.